Expression of the CD₁₁₇ Antigen on Multiple Myeloma and Its Significance.

BACKGROUND & OBJECTIVE: Leukocyte differentiation antigen CD₁₁₇ is one of the targets that tyrosine kinase selective inhibitors work on. CD₁₁₇, whether the cell surface is expressed and the quality of its expression, is highly correlated with the tyrosine kinase selective inhibitors. And whether Multiple myeloma (MM) cells express CD₁₁₇ and its expression quality is not reported domestic yet but only several reported overseas. In this study, CD₁₁₇ expressed in MM cells is evaluated, which provide an theoretical evidence for tyrosine kinase selective inhibitors used in the MM, meanwhile, the value of the CD₁₁₇ expressed in MM cells is estimated.

METHODS:CD₁₁₇,CD_56,CD₅₄ were measured by three -color flow cytometry with CD45/SSC gating strategy.

RESULTS:Of 48 patients with MM, 17(35.5%) CD₁₁₇ expression was positive in myeloma cells, and CD₅₆, CD₅₄ expression was positive in 39(81.2%), 48(100.0%), respectively. CD₁₁₇ expression in myeloma cells was low compared with CD₅₆, CD₅₄ in 48 patients with MM; CD₁₁₇ positive expression showed a positive correlation with myeloma cells in the bone marrow; CD₁₁₇ positive in IgG type of MM was 64%, higher than other types such as light chain or IgA.CD₁₁₇ positive showed no significant difference in different stage, untreated, relapsed and refractory patients (P>0.05, P>0.01); In untreated MM patient, chemotherapy of VAD in CD₁₁₇ positive patient, the effectiveness was 71.4%, compared with the reaction rate 66.7% in CD₁₁₇ negative, showed no significant difference (P>0.05).

CONCLUSIONS:CD_{117 </SU}